Diorio, Caroline
Shraim, Rawan
Vella, Laura A.
Giles, Josephine R.
Baxter, Amy E. http://orcid.org/0000-0002-1555-0713
Oldridge, Derek A.
Canna, Scott W.
Henrickson, Sarah E.
McNerney, Kevin O.
Balamuth, Frances
Burudpakdee, Chakkapong
Lee, Jessica
Leng, Tomas http://orcid.org/0000-0001-8069-3393
Farrel, Alvin
Lambert, Michele P. http://orcid.org/0000-0003-0439-402X
Sullivan, Kathleen E.
Wherry, E. John http://orcid.org/0000-0003-0477-1956
Teachey, David T. http://orcid.org/0000-0001-7373-8987
Bassiri, Hamid
Behrens, Edward M.
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA193776, X01HD100702-01, 5UG1CA233249)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Leukemia and Lymphoma Society (N/A)
Alex’s Lemonade Stand Foundation for Childhood Cancer (N/A)
Children’s Hospital of Philadelphia Frontier Programs
Article History
Received: 24 June 2021
Accepted: 25 November 2021
First Online: 10 December 2021
Competing interests
: DTT serves on advisory boards for Janssen, Sobi, and BEAM. HB has stock ownership in Kriya Therapeutics. SH serves on the advisory board for Horizon Pharma. MPL is an advisory board member for Octapharma and Shionogi, a consultant for Amgen, Novartis, Shionogi, Dova, Bayer, the United States Department of Justice, Sobi, Principia and Argenx and has received research funding from Sysmex, Novartis, Astra Zeneca Rigel, Principia, Argenx, Janssen, and Dova, and has served as a medical advisor for Rigel, Principia, the Platelet Disorder Support Association, CdLS Foundation and 22q11.2 Society. KES received personal fees from Elsevier, Enzyvant and Immune Deficiency Foundation. HB is a paid consultant for Kriya Therapeutics. EMB receives research funding from AB2Bio. E.J.W. is a founder of Surface Oncology and Arsenal Biosciences. E.J.W. is an inventor on a patent (US patent number 10,370,446) submitted by Emory University that covers the use of PD-1 blockade to treat infections and cancer. The other authors declare no competing interests.